MAPT and Alzheimer disease: This impairment in the activity of LMTM by symptomatic AD drugs could be reproduced in a tau transgenic mouse model for AD, and was found to depend on the brain's homeostatic responses to the activating affects that symptomatic drugs depend on for their ability to boost cognitive function temporarily (267).